FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1557478422> ?p ?o ?g. }

• W1557478422 abstract "Up to 75% of people with serious mental illness (SMI) such as schizophrenia and bipolar disorder have co-occurring substance use disorders (dual diagnosis). Dual diagnosis can have an adverse effect on treatment and prognosis of SMI.To evaluate the effects of risperidone compared to treatment with other antipsychotics (first-generation and other second-generation antipsychotics) used in people with serious mental illness and co-occurring substance misuse.On 6 January 2016 and 9 October 2017, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (including trial registers).We selected randomised trials of risperidone versus any other antipsychotic in people with SMI and substance abuse (dual diagnosis). We included trials meeting our inclusion criteria and reporting useable data. We excluded trials that either did not meet our inclusion criteria or met our inclusion criteria but did not report any useable data.We independently inspected citations and selected studies. For included studies, we independently extracted data and appraised study quality. For binary outcomes we calculated the risk ratios (RRs) and their 95% confidence intervals. For continuous outcomes we calculated the mean differences (MDs) and their 95% confidence intervals. We pooled data using random-effects meta-analyses and assessed the quality of evidence, creating a 'Summary of findings' table using the GRADE approach.We identified eight randomised trials containing a total of 1073 participants with SMI and co-occurring substance misuse. Seven of these contributed useable data to the review. There was heterogeneity in trial design and measurement. Risperidone was compared to clozapine, olanzapine, perphenazine, quetiapine and ziprasidone. Few trials compared risperidone with first-generation agents. Few trials examined participants with a dual diagnosis from the outset and most trials only contained separate analyses of subgroups with a dual diagnosis or were secondary data analyses of subgroups of people with a dual diagnosis from existing larger trials.For risperidone versus clozapine we found no clear differences between these two antipsychotics in the reduction of positive psychotic symptoms (1 randomised controlled trial (RCT), n = 36, mean difference (MD) 0.90, 95% CI -2.21 to 4.01, very low quality evidence), or reduction in cannabis use (1 RCT, n = 14, risk ratio (RR) 1.00, 95% CI 0.30 to 3.35, very low quality evidence), improvement in subjective well-being (1 RCT, n = 36, MD -6.00, 95% CI -14.82 to 2.82, very low quality evidence), numbers discontinuing medication (1 RCT, n = 36, RR 4.05, 95% CI 0.21 to 78.76, very low quality evidence), extrapyramidal side-effects (2 RCTs, n = 50, RR 2.71, 95% CI 0.30 to 24.08; I² = 0%, very low quality evidence), or leaving the study early (2 RCTs, n = 45, RR 0.49, 95% CI 0.10 to 2.51; I² = 34%, very low quality evidence). Clozapine was associated with lower levels of craving for cannabis (1 RCT, n = 28, MD 7.00, 95% CI 2.37 to 11.63, very low quality evidence).For risperidone versus olanzapine we found no clear differences in the reduction of positive psychotic symptoms (1 RCT, n = 37, MD -1.50, 95% CI -3.82 to 0.82, very low quality evidence), reduction in cannabis use (1 RCT, n = 41, MD 0.40, 95% CI -4.72 to 5.52, very low quality evidence), craving for cannabis (1 RCT, n = 41, MD 5.00, 95% CI -4.86 to 14.86, very low quality evidence), parkinsonism (1 RCT, n = 16, MD -0.08, 95% CI -1.21 to 1.05, very low quality evidence), or leaving the study early (2 RCT, n = 77, RR 0.68, 95% CI 0.34 to 1.35; I² = 0%, very low quality evidence).For risperidone versus perphenazine, we found no clear differences in the number of participants leaving the study early (1 RCT, n = 281, RR 1.05, 95% CI 0.92 to 1.20, low-quality evidence).For risperidone versus quetiapine, we found no clear differences in the number of participants leaving the study early (1 RCT, n = 294, RR 0.96, 95% CI 0.86 to 1.07, low-quality evidence).For risperidone versus ziprasidone, we found no clear differences in the number of participants leaving the study early (1 RCT, n = 240, RR 0.96, 95% CI 0.85 to 1.10, low-quality evidence).For many comparisons, important outcomes were missing; and no data were reported in any study for metabolic disturbances, global impression of illness severity, quality of life or mortality.There is not sufficient good-quality evidence available to determine the effects of risperidone compared with other antipsychotics in people with a dual diagnosis. Few trials compared risperidone with first-generation agents, leading to limited applicability to settings where access to second-generation agents is limited, such as in low- and middle-income countries. Moreover, heterogeneity in trial design and measurement of outcomes precluded the use of many trials in our analyses. Future trials in this area need to be sufficiently powered but also need to conform to consistent methods in study population selection, use of measurement scales, definition of outcomes, and measures to counter risk of bias. Investigators should adhere to CONSORT guidelines in the reporting of results." @default.
• W1557478422 created "2016-06-24" @default.
• W1557478422 creator A5050824346 @default.
• W1557478422 creator A5070602460 @default.
• W1557478422 creator A5073216705 @default.
• W1557478422 creator A5084912060 @default.
• W1557478422 date "2018-01-22" @default.
• W1557478422 modified "2023-10-18" @default.
• W1557478422 title "Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse" @default.
• W1557478422 cites W1131189 @default.
• W1557478422 cites W134915759 @default.
• W1557478422 cites W134927359 @default.
• W1557478422 cites W1475474724 @default.
• W1557478422 cites W1495797590 @default.
• W1557478422 cites W1544423098 @default.
• W1557478422 cites W1556485502 @default.
• W1557478422 cites W1591259115 @default.
• W1557478422 cites W1629537514 @default.
• W1557478422 cites W1954888178 @default.
• W1557478422 cites W1960792000 @default.
• W1557478422 cites W1963512293 @default.
• W1557478422 cites W1964162160 @default.
• W1557478422 cites W1970294061 @default.
• W1557478422 cites W1972559070 @default.
• W1557478422 cites W1973736931 @default.
• W1557478422 cites W1974055131 @default.
• W1557478422 cites W1974297784 @default.
• W1557478422 cites W1974702488 @default.
• W1557478422 cites W1975271154 @default.
• W1557478422 cites W1976319647 @default.
• W1557478422 cites W1977185679 @default.
• W1557478422 cites W1977725618 @default.
• W1557478422 cites W1978040764 @default.
• W1557478422 cites W1979826615 @default.
• W1557478422 cites W1985674713 @default.
• W1557478422 cites W1986864326 @default.
• W1557478422 cites W1987364343 @default.
• W1557478422 cites W1988863452 @default.
• W1557478422 cites W1991696949 @default.
• W1557478422 cites W1992857340 @default.
• W1557478422 cites W1993190590 @default.
• W1557478422 cites W1997435469 @default.
• W1557478422 cites W1999646972 @default.
• W1557478422 cites W1999689270 @default.
• W1557478422 cites W1999948756 @default.
• W1557478422 cites W2000936213 @default.
• W1557478422 cites W2006062215 @default.
• W1557478422 cites W2011357127 @default.
• W1557478422 cites W2014347408 @default.
• W1557478422 cites W2015557371 @default.
• W1557478422 cites W2016117636 @default.
• W1557478422 cites W2017134978 @default.
• W1557478422 cites W2018679306 @default.
• W1557478422 cites W2019401805 @default.
• W1557478422 cites W2020065445 @default.
• W1557478422 cites W2020539828 @default.
• W1557478422 cites W2020615571 @default.
• W1557478422 cites W2020844317 @default.
• W1557478422 cites W2021782736 @default.
• W1557478422 cites W2022647799 @default.
• W1557478422 cites W2023839473 @default.
• W1557478422 cites W2024374498 @default.
• W1557478422 cites W2025243014 @default.
• W1557478422 cites W2028877810 @default.
• W1557478422 cites W2029986826 @default.
• W1557478422 cites W2030496540 @default.
• W1557478422 cites W2031012269 @default.
• W1557478422 cites W2032712358 @default.
• W1557478422 cites W2034861437 @default.
• W1557478422 cites W2037034236 @default.
• W1557478422 cites W2039828875 @default.
• W1557478422 cites W2044104071 @default.
• W1557478422 cites W2047151451 @default.
• W1557478422 cites W2048029383 @default.
• W1557478422 cites W2052193636 @default.
• W1557478422 cites W2058874144 @default.
• W1557478422 cites W2059645940 @default.
• W1557478422 cites W2064346475 @default.
• W1557478422 cites W2067567375 @default.
• W1557478422 cites W2070893229 @default.
• W1557478422 cites W2074666011 @default.
• W1557478422 cites W2075107167 @default.
• W1557478422 cites W2076410053 @default.
• W1557478422 cites W2077905124 @default.
• W1557478422 cites W2081225070 @default.
• W1557478422 cites W2081978467 @default.
• W1557478422 cites W2082559750 @default.
• W1557478422 cites W2085203458 @default.
• W1557478422 cites W2089868642 @default.
• W1557478422 cites W2090481799 @default.
• W1557478422 cites W2093729667 @default.
• W1557478422 cites W2096613914 @default.
• W1557478422 cites W2097505547 @default.
• W1557478422 cites W2098831733 @default.
• W1557478422 cites W2098931866 @default.
• W1557478422 cites W2099576957 @default.
• W1557478422 cites W2100637685 @default.
• W1557478422 cites W2104675861 @default.
• W1557478422 cites W2106493693 @default.
• W1557478422 cites W2107201157 @default.

• next